LIPITOR SUMMARY
Lipitor® (atorvastatin calcium) is a synthetic lipid-lowering agent. Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age >/= 55 years, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Lipitor is indicated to:
-
Reduce the risk of myocardial infarction
-
Reduce the risk for revascularization procedures and angina
Hypercholesterolemia
Lipitor is indicated:
-
as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson
Types IIa and IIb);
-
as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson
Type IV);
-
for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson
Type III) who do not respond adequately to diet;
-
to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are unavailable;
-
as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present:
-
LDL-C remains >/= 190 mg/dL or
-
LDL-C remains >/= 160 mg/dL and:
-
there is a positive family history of premature cardiovascular disease or
-
two or more other CVD risk factors are present in the pediatric patient
|
